We are proud to be among the first investors and long-term partners to industry leaders who are empowering individuals and businesses through the innovative use of AI and other transformative technologies.
Imagene provides a disruptive, AI-based genomic testing solution to leverage the patient’s historical data for personalized therapy. Cancer diagnostic focus on pathological and molecular testing. Both are conducted by advanced technology which depends on limited amount of tissue, and therefore does not allow wide and extensive diagnosis. Further, genomic analysis, infrastructure and personnel are highly expensive and the overall diagnosis require prolong time to report. These four factors can be improved
Imagene believes that no structure and assumptions should become a barrier to personal treatment. They bring the potential of accurate, fast, low cost, actionable, standardized, and routine screening to all cancer patients